Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma
Authors:
- Chase W. KwonCKChase W. Kwon
- Rajini K. MurthyRMRajini K. Murthy
- Ragini KudchadkarRKRagini Kudchadkar
- Benjamin K. StoffBSBenjamin K. Stoff
Open Access
- 1 October 2020
- journal article
- Published by Elsevier in JAAD Case Reports
- Vol. 6 (10) , 1045-1047
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
- Merck
This publication has 7 references indexed in Scilit:
- Cutaneous Adverse Reactions of Anticancer AgentsDermatologic Clinics, 2019
- Lichen planus pemphigoides developing from patient with non‐small‐cell lung cancer treated with nivolumabThe Journal of Dermatology, 2019
- Nivolumab-Induced Lichen Planus Pemphigoides2019
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapyJournal of the American Academy of Dermatology, 2018
- Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodiesCurrent Opinion in Oncology, 2016
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyEuropean Journal of Cancer, 2016
- Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohortJournal of the American Academy of Dermatology, 2016